SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

PHARMACEUTICAL APPLICATIONS OF ARTIFICIAL INTELLIGENCE

Shailesh Kr. Yadav[1], Shubham Singh[2]
S.N College of Pharmacy, Lakhauwa , Jaunpur

ABSTRACT
Artificial intelligence has been more prevalent in pharmaceutical technology throughout time, and its application can improve understanding of the interactions between various formulation and process parameters while also saving time and money. Fuzzylogic, neural networks, and genetic algorithms are quickly developing technologies that may be used in the production and processing of pharmaceuticals. Applications of several kinds of artificial intelligence are covered in this article.
KEYWORDS: *Artificial Intelligence, Artificial Neural Network, Genetic Algorithms, Fuzzy Logic, Controlled Release Tablets, Immediate Release Tablets.*

1. INTRODUCTION

The study of complicated information processing issues that have their roots in biological information processing is known as artificial intelligence (AI). Finding practical information processing issues and providing an abstract explanation of how to resolve them is the primary goal of the course. In mathematics, such an explanation is referred to as a method and is equivalent to a theorem. The study of designing and implementing algorithms for data analysis, learning, and interpretation is known as artificial intelligence. Therefore, statistical and machine learning, pattern recognition, clustering, similarity-based techniques, logics, and probability theory, as well as biologically motivated methods like neural networks and fuzzy modelling, are all included in the broadly defined field of artificial intelligence (AI), which is referred to as "computational intelligence". The process of making pharmaceutical drugs is quite complicated, from developing the formulation to the final product. Multivariate interactions between raw materials and process parameters are a part of this process. These interactions are critical to the final product's quality and process ability.

2.AI IN DRUG RESEARCH

AI has transformed drug discovery and research in a number of ways. The following are some of AI's most significant achievements in this field:

2.1. Identification of the Target

To find possible therapeutic targets, AI systems can examine a variety of data sources, including genomic, proteomic, and clinical data. AI helps create drugs that can alter biological processes by identifying molecular pathways and targets linked to disease.

2.2. Online Examination

AI makes it possible to efficiently screen large chemical libraries in order to find therapeutic candidates that are highly likely to bind to a particular target. AI saves time and money by helping researchers prioritize and choose compounds for experimental testing by modeling chemical interactions and forecasting binding affinities.

2.3. Relationship between Structure and Activity (SAR)

AI modeling can create connections between a compound's biological action and its chemical structure. By creating compounds with desired characteristics including high potency, selectivity, and advantageous pharmacokinetic profiles, researchers are able to optimize therapeutic prospects.

2.4. Innovative Drug Design

AI computers can suggest new chemical compounds that resemble drugs by using generative models and reinforcement learning. AI broadens the chemical universe and facilitates the creation of novel therapeutic candidates by learning from chemical libraries and experimental data.

2.5. Drug Candidate Optimization

AI systems can evaluate and improve medication candidates by taking into account a number of variables, such as pharmacokinetics, safety, and efficacy. This aids scientists in optimizing therapeutic compounds to increase their efficacy while reducing any adverse effects.


SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

2.6. Drug Repurposing

AI techniques can analyze large-scale biomedical data to identify existing drugs that may have therapeutic potential for different diseases. By repurposing approved drugs for new indications, AI accelerates the drug discovery process and reduces costs.

2.7. Toxicity Prediction

AI systems can predict drug toxicity by analyzing the chemical structure and characteristics of compounds. Machine learning algorithms trained on toxicology databases can anticipate harmful effects or identify hazardous structural properties. This helps researchers prioritize safer chemicals and mitigate potential adverse responses in clinical trials



Artificial Neural Networks (ANNs)

Neural networks are now regarded as one of the best computing tools ever created, having gained respect from scientists and engineers in recent years. The capacity of neural networks to mimic the brain's assimilation by example is largely responsible for this elation. Even in the face of inadequate knowledge, this network takes decisions and draws inferences. Furthermore, neural networks mimic the brain's creative process when it comes to adapting to a new circumstance on a rudimentary level. The pattern recognition powers of the brain's neural networks are modelled by artificial neural network (ANN) technology. Like a single neuron in the brain, an artificial neuron unit processes information from a variety of outside sources before making decisions. It's interesting to note that ANN uses analogs of adaptive biological neurons to mimic the biological nervous system. Artificial neurons and multiple processing units (PE) make up an ANN. The strength of the connections between each unit varies and is determined by weights or factors. The ANN simulates how the human brain functions and could realize scientists' long-held goal of creating machines with human-like thought processes. By modeling data and identifying patterns for intricate multifaceted situations, artificial neural networks (ANNs) mimic the learning and generalization processes of the human brain. The ability of an ANN model to generalize

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

the link between independent and dependent variables without the need for a particular mathematical function distinguishes it from a statistical model.

3.GENETIC ALGORITHM

A genetic algorithm (GA) is a type of search heuristic used in artificial intelligence that mimics the process of natural development. This heuristic, sometimes known as a met heuristic, is frequently employed to provide practical answers to search and optimization issues. A probing method called a genetic algorithm is utilized to simultaneously solve optimization and search problems. In the context of drug design and chemometrics, these stochastic optimization techniques offer a potent way to conduct directed random searches across a vast problem space. Two definitions are required for a genetic algorithm: the fitness function and the genetic representation of solutions. The first step in solving any problem is to sketch the genetic representation. Establishing a fitness function for the issue comes after the genetic representation.

The fitness function varies depending on the problem. The Genetic Algorithm begins by randomly initializing the population of solutions, which is made up of a number of randomly created individual solutions. The population's size depends on the type of issue. There could be hundreds or thousands of distinct solutions in it. The fitness function is assessed for every population separately in the following.

The final step is population reproduction, where genetic operators like crossover, mutation, and selection are used to create the next generation of the population. 8 In drug design, a molecule is defined as the input to GA and coded with a binary string. A genetic operator is used to generate a large number of solutions, and the best population is chosen and used to create new populations until the desired solution is achieved.

Fuzzy Logic

Pre-clinical in vitro and in vivo research, lead optimization, and lead and target discovery are the first steps in the rigorous, drawn-out, and sequential process of drug discovery and design. In order to tackle difficulties, computer science, electrical engineering, and electronics and communication engineering formerly used computational methodologies. But the employment of these methods today has altered the course of medication design and discovery during the past 20 years. Artificial neural networks, genetic algorithms, genetic programming, evolutionary programming, evolutionary strategy, and others are examples of these techniques. The science of reasoning, inference, and thinking known as fuzzy logic acknowledges and applies the fact that everything is a question of degree in the real world. The fuzzy set differs from classical set theory in that its bounds are not as clear.

Accordingly, in fuzzy sets, the value lies between $0 < \mu \geq 1$, where μ is the membership function, but in traditional set theory, the value is either 0 or 1. Fuzzy inference is the most crucial aspect of fuzzy logic. Based on fuzzy set theory, fuzzy inference systems are thought to be appropriate for handling a wide range of real-world issues that are complicated, ambiguous, and involve a lack of understanding of the underlying physical laws. Fuzzy rule-based models, which use linguistically interpretable rules to model the interactions between system variables, are the most significant application of fuzzy set theory.
When it comes to specifying goal qualities for optimizations, fuzzy logic can be quite helpful .

For instance, the formulator may be aiming for a 200 s tablet disintegration time, meaning that any value below that has a desirability of 1 (i.e., 100%).
However, contrary to what strict logic would require, a tablet that dissolves in 210 seconds is not completely unattractive and may instead be given a desirability rating of 0.9.
The fuzzy set's fundamental steps in process modeling are as follows:

> Organize the datasets for input and output.
> Sorting the output set into clusters
> Connect the output to the fuzzy inputs.
> Determine the important variables.
> Utilize the rule-based inference method.

4. APPLICATION OF AI IN PHARMACEUTICAL RESEARCH

1. In Formulation

Controlled release tablets

Hussain and associates from the University of Cincinnati (OH, USA) carried out the first study utilizing neural networks for pharmaceutical formulation modeling. The in vitro release properties of a variety of medications distributed in matrices made from different hydrophilic polymers were modelled in a number of investigations. Neural networks with a single hidden layer were shown to perform rather well in all scenarios when it came to drug release prediction. Overall, the outcomes were similar to those produced by statistical analysis; but, performance suffered when predictions that went outside the bounds of the input data were made.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

Although there was no attempt to use genetic algorithms to enhance the formulas, the researchers did suggest the idea of neural network-based computer-aided formulation design. In a more recent study, researchers from the University of Ljubljana (Slovenia) and the pharmaceutical company KRKA dd (Smerjeska, Slovenia) used neural networks to optimize the formulation of diclofenac sodium from a matrix tablet made from cetyl alcohol and predict the rate of drug release using two- and three-dimensional response surface analysis. There may be a chance to produce many formulations with the same release profile because non-linear correlations between the release rate and the amounts of the substances employed in the formulation were discovered.

Immediate release tablets

Just around three years ago, two investigations were conducted in this field. Turkoglu and colleagues from the University of Marmara (Turkey) and the University of Cincinnati11 modeled hydrochlorothiazide tablet formulations using both statistics and neural networks. In an effort to optimize tablet strength or choose the optimum lubricant, the networks generated were utilized to create three-dimensional plots of massing time, compression pressure, and crushing strength, or drug release, massing time, and compression pressure.

Despite trends being noted, no ideal formulations were provided. The patterns were similar to those produced by statistical techniques. Genetic algorithms were used to create and optimize similar neural network models. It was discovered that the limits imposed on the formulation's constituent levels and the relative weight given to the output parameters determined the ideal formulation. It was only possible to achieve low friability and high tablet strength at the expense of disintegration time. Lactose was the recommended diluent in every instance, and fluidized bed was the recommended granulating method.

2. In Product Development

The process of developing pharmaceutical products is a multivariate optimization problem. Formulation and process factors are optimized. The capacity of artificial neural networks to generalize is one of its most advantageous features. These characteristics make them appropriate for resolving issues related to formulation optimization in the development of pharmaceutical products. When investigating the influence of various factors (like formulation and compression parameters) on tablet qualities (like dissolution), ANN models demonstrated superior fitting and predictive skills in the development of solid dosage forms.

ANNs were a helpful tool for creating drug delivery systems based on micro emulsions that required less experimentation. The phase behavior of quaternary microemulsion-forming systems made up of water, oil, and two surfactants was predicted using ANNs. In order to leverage this kind of technology in the assessment and design of pulmonary drug-delivery systems, ANN was also utilized to mimic aerosol behavior. Fuzzy logic is a very effective problem-solving method for controlling and making decisions. From input data, it generates highly helpful rules in the style of "if... so... then." Neural networks and fuzzy logic can be combined to create neuro fuzzy logic. This combination gives the method greater adaptability and capacity and yields potent outcomes.




Fig :- Working of genetic algorithm

AI Tools' Limitations

AI-based models have many drawbacks despite their advantages, including the requirement for huge datasets, possible biases, and interpretability issues. Therefore, to guarantee the safety and effectiveness of medications, AI-based models should be employed in conjunction with conventional experimental techniques. The following highlights a few of the restrictions:

1. Insufficient Openness

AI models employ intricate algorithms and are frequently referred to as "black boxes" since it is challenging to comprehend how the model makes its predictions. Gaining regulatory approval for AI-based drug development tools may be difficult due to this lack of transparency since it may be difficult to show that the model is producing accurate and trustworthy predictions.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

2. Limited Data Accessibility

For AI models to make accurate predictions, a substantial amount of data is needed. However, there may occasionally be a lack of data for a specific medication or demographic, which could result in biased or less accurate forecasts. For example, there may be little data available for rare disorders, which might make creating AI models extremely difficult.

3. Data Biases

The quality of the data used to train AI models determines their effectiveness and accuracy. Predictions made from incomplete or biased data may likewise be biased. One major issue in the field of pharmacology is the homogeneity of patient populations in clinical trials.

4. Incapacity to Add New Information

It might be difficult to update or add fresh data to an AI model once it has been trained. In the context of drug development procedures, where fresh knowledge and data are always coming, this might be a serious restriction. For instance, an AI model could need to be updated to account for new information as new medications are developed or as more data is gathered from clinical trials.

5. Limited Capacity to Take Variability Into Account

Large datasets are typically used to train AI models, which may be skewed toward the average responses found in the data. Because of this, the models might not be able to predict drug responses for people whose responses differ greatly from the norm.

CONCLUSION AND FUTURE PERSPECTIVES

In this context, artificial intelligence is widely defined as the study of creating and using algorithms for data analysis, learning, and interpretation. AI, which is collectively referred to as "computational intelligence," combines several areas of statistical and machine learning, pattern recognition, logic, and probability theory with biologically motivated techniques like neural networks, evolutionary computing, or fuzzy modeling.

Medical decision-making has greatly benefited from the use of ANN, particularly in the areas of disease diagnosis, categorization, and modeling. ANNs are an excellent tool for data analysis and modeling because of their ability to learn, identify patterns, and generalize.

REFERENCES

1. *Duch W., Swaminathan K., Meller J., Artificial Intelligence Approaches for Rational Drug Design and Discovery. Current Pharmaceutical Design, 2007;13: 00.*
2. *Sutariya V.,Groshev A., Sadana P., Bhatia D., Pathak Y., Artificial Neural Network in Drug Delivery and Pharmaceutical Research. The Open Bioinformatics Journal,2013; 7: 49-62.*
3. *Agatonovic-Kustrin, S., Beresford, R.,"Basic concepts of artificial neural network (ANN)modeling and its application in pharmaceutical research.",2000, Journal of Pharmaceutical and Biomedical Analysis 22, 717 727.*
4. *Raymond C., Rowe and Ronald J., Roberts.,Artificial intelligence in pharmaceutical product formulation: neural computing and emerging technologies." Research focus 1998; 1: 5.*
5. *Yadav G., Kumar Y., Sahoo G., Role of the Computational Intelligence in Drugs Discovery and Design: Introduction, Techniques and Software." International Journal of Computer Applications 2012; 51; 10.*
6. *Bhargavi P, Jyoti S., " Soil classification using mining techniques. International journal of engineering trends and technology," 2011.*
7. *Lad K., "The Role of Artificial Intelligence Tools in Pharmaceutical Industries: Special Reference to Expert System and Automation Tools." Research paper, 2015; 4: 483-484.*
8. *Buke, A., Paradkar A., Marcel de Matas; Ozgen Ozer; Guneri, T., and York,P., Quality by Design Approach: Application of Artificial Intelligence Techniques of Tablets Manufactured by Direct Compression. A QbD Approach for Direct Compressed Tablet Formulation. 2012; 13: 4.*
9. *Hayes C., Gedeon T., Hyperbolicity of the fixed point set for the simple genetic Algorithm. Theorical Computer Science, 2010; 411:24-29*
10. *Arabgol S, Hoo Sang Ko, Application of artificial neural network and genetic algorithm to health care waste prediction. JAISCR 2016; 3(3): 243-250.*
11. *Chakraborty RC., "Fundamentals of genetic algorithms." AI course 2010, lecture 39-40.*
12. *Melanie M. An introduction to genetic algorithms." A bradford book the MIT press Cambridg, Massachusetts. London, England, 1999, Fifth printing.*
13. *Goldberg D., Genetic algorithms in search, optimization and machine learning. Addison Wesley.", 1989.*
14. *Man K. F, Tang K. S, Kwong S., Genetic algorithms: concepts and designs, chapter 1-10.*